Jones v. Saul

CourtDistrict Court, D. Delaware
DecidedApril 5, 2022
Docket1:20-cv-01074
StatusUnknown

This text of Jones v. Saul (Jones v. Saul) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Saul, (D. Del. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE DORCAS R. JONES, ) ) Plaintiff, ) ) v. ) Civil Action No. 20-1074-SRF ) KILOLO KIJAKAZI,' ) Acting Commissioner of Social Security, ) ) Defendant, ) ) MEMORANDUM OPINION? Plaintiff Dorcas R. Jones (“Plaintiff”) filed this action pursuant to 42 U.S.C. §§ 405(g) on August 18, 2020 against the defendant Kilolo Kijakazi, the Acting Commissioner of the Social Security Administration (the “Commissioner”). (D.I. 2) Plaintiff seeks judicial review of the Commissioner’s May 20, 2019 final decision denying Plaintiff's claim for disability insurance benefits (“DIB”) under Title II of the Social Security Act (the “Act”), 42 U.S.C. §§ 401-433. Currently before the court are cross-motions for summary judgment filed by Plaintiff and the Commissioner.? (D.I. 22; D.I. 28) For the reasons set forth below, I recommend that the court DENY Plaintiff's motion for summary judgment (D.I. 22), and GRANT the Commissioner’s cross-motion for summary judgment (D.I. 28).

' Kilolo Kijakazi became the Acting Commissioner of Social Security on July 9, 2021. Therefore, pursuant to Rule 25(d) of the Federal Rules of Civil Procedure, Ms. Kijakazi is substituted as Defendant in place of Andrew Saul. 2 On December 9, 2021, the parties consented to the jurisdiction of a magistrate judge to conduct all proceedings in this matter through final judgment, pursuant to 28 U.S.C. § 636(c). (D.I. 24) 3 The briefing on the pending motions is found at D.I. 23, D.L. 30, and D.L. 31.

I. BACKGROUND A. Procedural History Plaintiff protectively filed an application for DIB on April 5, 2017, alleging a disability onset date of January 18, 2017 due to panic attacks, agoraphobia, restlessness, generalized anxiety disorder, and extreme anxiety. (D.I. 11 at 183-85, 210) Plaintiff's claims were denied initially in June 2017 and upon reconsideration in December 2017. (/d. at 78, 93) At Plaintiffs request, an administrative law judge (“ALJ”) held a hearing on May 2, 2019. (Ud. at 48-77) The ALJ issued an unfavorable decision on May 20, 2019, finding that Plaintiff was capable of a full range of work at all exertional levels, with some nonexertional limitations. (D.I. 11 at 14-24) The Appeals Council subsequently denied Plaintiff's request for review of the ALJ’s decision, making the ALJ’s decision the final decision of the Commissioner. (/d. at 5-7) Plaintiff brought this civil action challenging the ALJ’s decision on August 18, 2020. (D.I. 2) Plaintiff filed the pending motion for summary judgment on December 9, 2021 (D.1I. 22), and the Commissioner cross-moved for summary judgment on March 11, 2022 (D.I. 28). Briefing is now complete on the pending motions. B. Medical History Plaintiff was 44 years old on her alleged disability onset date of January 18, 2017. (DI. 11 at 23) The ALJ found that Plaintiff had the following severe impairments: panic attacks, agoraphobia, generalized anxiety disorder, and depressive disorder. (/d. at 17) The court focuses its summary of the medical evidence on the records relevant to the challenges raised by Plaintiff. Plaintiff's appeal is largely focused on whether the ALJ’s determination of Plaintiffs residual functional capacity (“RFC”) accounts for functional limitations related to Plaintiff's

agoraphobia.* 1. Medical evidence Beginning in February 2015, Plaintiff saw Nadeem Afzal, M.D. for psychiatric treatment. (D.I. 11 at 460) At the time, Dr. Afzal indicated that Plaintiff wanted to stop taking her psychiatric medications and switch completely to herbal supplements, and she reported that her symptoms were under control with the combination of Zoloft and herbal supplements. (/d.) Dr. Afzal observed signs of anxiety and moderate depression, but her behavior was otherwise normal. (/d. at 461) Subsequent treatment notes through the end of 2015 disclosed stable findings, partial treatment response to medication, and no medication side effects. (Id. at 463- 72) By 2016, she was showing no signs of depression or anxiety, and she began tapering her Zoloft dosage in November 2016. (id. at 473-87) However, she experienced anxiety and withdrawal symptoms in early 2017 as a result of the tapering, and Dr. Afzal restarted her Zoloft prescription. (/d. at 488) Plaintiff visited the emergency room on January 18, 2017 due to an acute panic attack, and she was discharged with a prescription for Kanax and instructions to follow up with Dr. Afzal. (D.I. 11 at 283, 288-89) The following day, Dr. Afzal observed that Plaintiff's anxiety symptoms were worse. (/d. at 491) He increased her Zoloft dosage and instructed her to start taking Xanax as well. (/d. at 492) Plaintiff's symptoms continued to get worse that month, and she expressed concern that she would lose her job. (/d. at 495)

‘ The U.S. Department of Health and Human Services, National Institute of Mental Health defines “agoraphobia” as “an anxiety disorder that involves intense fear and anxiety of any place or situation where escape might be difficult. Agoraphobia involves avoidance of situations such as being alone outside of the home; traveling in a car, bus, or airplane; or being in a crowded area.” See https://www.nimh.nih.gov/health/statistics/agoraphobia (last visited on April 4, 2022).

In early February, Plaintiff indicated that her panic attacks and anxiety had improved, although she still appeared very anxious. (D.I. 11 at 498) Dr. Afzal increased her Zoloft dosage. (id.) On February 13, 2017, she was voluntarily admitted to the Rockford Center for five days due to worsening anxiety and panic attacks. (/d. at 364-69) There, her Zoloft and Kanax prescriptions were discontinued, and she was switched to Prozac, Klonopin, gabapentin, and Seroquel. (/d. at 367) Upon her discharge, she was not anxious and was clinically stable, with a discharge prognosis of “fair.” (/d. at 368-70) Subsequent treatment notes from Dr. Afzal indicate that Plaintiff showed a partial treatment response and her anxiety improved overall, but she still showed signs of anxiety and her Prozac dosage was increased. (/d. at 501, 504, 507, 510) Plaintiff also saw psychotherapist John Stephen Parker, M.S., L.P.C. from February to May of 2017. (D.I. 11 at 373-96) Mr. Parker’s notes describe Plaintiff's self-reports about her anxiety and panic attacks, with a consistent focus on her interpersonal difficulties. (/d.) Plaintiff suggested that she should only drive or perform activities of daily living at times when she has no anxiety. (/d. at 381) Plaintiff reported having panic attacks and worsening anxiety in May 2017 as a result of relationship difficulties, which interfered with her ability to walk, write, and do laundry. (D.I. 11 at 514, 517, 520) Dr. Afzal indicated that Plaintiff was experiencing anxiety and moderate depression, and he increased her Prozac dosage again. (/d.) Plaintiff also visited her primary care provider, nurse practitioner Roberta Beiso, for her anxiety and depression between May and July 2017. (dd. at 599-604, 606-07) During a visit in June, Plaintiff's care provider reported that she was tearful and upset throughout the appointment, although she was not experiencing a crisis Situation at the time. (/d. at 604)

Plaintiff's mood had improved by mid-July. (D.L. 11 at 599-601) Days later, however, Dr. Afzal reported that Plaintiff had experienced a setback resulting in tearfulness, increased panic attacks, and reduced ability to function independently. (/d. at 522) Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bowen v. Yuckert
482 U.S. 137 (Supreme Court, 1987)
Barnhart v. Thomas
540 U.S. 20 (Supreme Court, 2003)
Thelosen v. Commissioner of Social Security
384 F. App'x 86 (Third Circuit, 2010)
Kacee Chandler v. Commissioner Social Security
667 F.3d 356 (Third Circuit, 2011)
Roseann Zirnsak v. Commissioner Social Security
777 F.3d 607 (Third Circuit, 2014)
Dennis Hoyman v. Commissioner Social Security
606 F. App'x 678 (Third Circuit, 2015)
Scatorchia v. Commissioner of Social Security
137 F. App'x 468 (Third Circuit, 2005)
Douglas Gross v. Commissioner Social Security
653 F. App'x 116 (Third Circuit, 2016)
Biestek v. Berryhill
587 U.S. 97 (Supreme Court, 2019)
Turby v. Barnhart
54 F. App'x 118 (Third Circuit, 2002)
Moore v. Astrue
851 F. Supp. 2d 1131 (N.D. Illinois, 2012)
Schuster v. Astrue
879 F. Supp. 2d 461 (E.D. Pennsylvania, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Jones v. Saul, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-saul-ded-2022.